[Frontiers in Bioscience E4, 2233-2252, January 1, 2012]

Mitochondrial dysfunction in cholestatic liver diseases

Alessandro Arduini1, Gaetano Serviddio2, Ana M. Tormos1, Maria Monsalve3, Juan Sastre1

1Department of Physiology, School of Pharmacy, University of Valencia, Valencia, Spain, 2Department of Medical and Occupational Sciences, University of Foggia, Foggia, Italy, 3Centro Nacional de Investigaciones Cardiovasculares, Consejo Superior de Investigaciones Cientificas, CNIC, CSIC, Madrid, Spain

TABLE OF CONTENTS

1. Abstract
2. Cholestatic liver diseases
3. Impairment of mitochondrial function in cholestatic liver disease
4. Mitochondrial biogenesis in cholestatic liver disease
5. Mitochondrial-mediated apoptosis in cholestatic liver disease 5.1. General aspects
5.2. Bile acids promote apoptosis in liver
5.3. Apoptosis in liver cholestasis: time course and mechanisms
5.4. Anti-apoptotic response to cholestatic injury
6. Mitochondrial oxidative stress in cholestatic liver disease
7. Dual role of inflammation in chronic cholestasis
8. Cholestatic liver disease as a secondary mitochondriopathy
9. Mitochondria as putative targets for therapeutic intervention in cholestasis
10. Concluding remarks
11. Acknowledgement
12. References

1. ABSTRACT

Cholestatic liver diseases are characterized by blockade of bile flow from the liver to the intestine, and accumulation of hydrophobic bile acids in the liver and plasma. As a consequence an inflammatory response evolves associated with increased apoptosis, oxidative stress, and eventually fibrosis. Cholestasis is associated with profound metabolic changes, alterations in the mitochondrial function, decreased fatty acid oxidation, and increased glycolisis. Mitochondria play a central role in the development of this liver disease because they mediate death receptor signaling - triggered by inflammatory cytokines or bile acids - and contribute to oxidative damage, metabolic disorder, and onset of fibrosis. During the pathogenesis of biliary cirrhosis mitochondria's need for renewal is hampered by a blunted mitochondrial biogenesis. Lack of stimulation of mitochondrial renewal helps to explain mitochondrial impairment in long-term cholestasis. The marked depletion of mitochondrial DNA and occurrence of mitochondrial DNA deletions are probably relevant contributors to the progression of this severe disease. All these findings certainly support the consideration of long-term cholestasis as a secondary mitochondrial hepatopathy.